In summary, this study demonstrated that overactivation of Akt is associated with MEK inhibitor resistance in colorectal cancer cells harboring KRAS or BRAF mutations and that Akt inhibitor overcame MEK inhibitor resistance. The gene discussed is BRAF; the disease is colorectal cancer.